|Home | About | Journals | Submit | Contact Us | Français|
Babesia are emerging health threats to humans and animals in the United States. A collaborative effort of multiple disciplines to attain optimal health for people, animals and our environment, otherwise known as the One Health concept, was taken during a research workshop held in April 2009 to identify gaps in scientific knowledge regarding babesioses. The impetus for this analysis was the increased risk for outbreaks of bovine babesiosis, also known as Texas cattle fever, associated with the re-infestation of the U.S. by cattle fever ticks.
The involvement of wildlife in the ecology of cattle fever ticks jeopardizes the ability of state and federal agencies to keep the national herd free of Texas cattle fever. Similarly, there has been a progressive increase in the number of cases of human babesiosis over the past 25 years due to an increase in the white-tailed deer population. Human babesiosis due to cattle-associated Babesia divergens and Babesia divergens-like organisms have begun to appear in residents of the United States. Research needs for human and bovine babesioses were identified and are presented herein.
The translation of this research is expected to provide veterinary and public health systems with the tools to mitigate the impact of bovine and human babesioses. However, economic, political, and social commitments are urgently required, including increased national funding for animal and human Babesia research, to prevent the re-establishment of cattle fever ticks and the increasing problem of human babesiosis in the United States.
Babesioses are emerging tick-borne diseases in humans and animals caused by the intraerythrocytic apicomplexan protozoa Babesia spp . More than 100 species of Babesia have been described, several remain to be fully described, and it is likely that many more species remain to be discovered . While ticks are second only to mosquitoes as worldwide vectors of human diseases, they are the most relevant vectors of disease-causing pathogens in domestic and wild animals . Climate, host movement, animal husbandry practices, vector distribution and vector population changes affect the epidemiology of babesioses and other tick-borne diseases. Changes in these factors could result in enhanced Babesia transmission across vertebrate species by infected ticks and a greater role of certain wildlife in amplifying tick vector populations .
The One Health concept, which is used here to define the collaborative effort of multiple disciplines to attain optimal health for people, animals and our environment, was applied to a workshop organized to identify gaps in the scientific knowledge regarding bovine and human babesioses in the United States . Emphasis was placed on the potential threat of reintroduction of cattle fever ticks (CFT) into the U.S. and concomitant increase in the risk for outbreaks of bovine babesiosis, but we also addressed the emerging problem of human babesiosis because collaboration between entomologist, epidemiologists, physicians, veterinarians, and related health-sciences experts can most effectively address these closely related health issues.
Discussions by the workshop participants focused on (I) epidemiology and surveillance, (II) ecology and biology of tick vectors and wildlife, (III) diagnosis, treatment, and prevention, (IV) integrated approaches for sustainable CFT eradication, and (V) tick vaccines in the context of bovine and human babesioses. Here, we present a list of research needs for bovine and human babesioses as the outcome of the workshop exercise. The translation of this research is expected to provide veterinary and public health systems with the tools to mitigate the impact of tick-borne babesioses.
Bovine, canine, and equine babesioses are among the most economically relevant infections of domestic animals. Infestations with CFT, Rhipicephalus (Boophilus)microplus and R. (B.)annulatus, economically impact cattle production in tropical and subtropical regions of the world. They cause damage directly by reducing weight gain and milk production and are vectors of pathogens that cause bovine babesiosis (Babesia bovis and B. bigemina), also known as cattle tick fever or Texas cattle fever, and the etiologic agent of anaplasmosis (Anaplasma marginale) [4,6,7]. The U.S. Cattle Fever Tick Eradication Program (CFTEP) was initiated in 1906 to free the national cattle herd from bovine babesiosis . Subsequently, CFT were officially eradicated from the U.S. in 1943 with the exception of a permanent quarantine zone that remains in place today in South Texas along the border with Mexico. It is estimated that the livestock industry realizes annual savings of at least 3 billion dollars at today's currency rate since the U.S. was declared free of CFT and bovine babesiosis . However, the apparent re-infestation of the U.S. by CFT, which is thought to be due primarily to changes affecting the ecology of ticks and wild ungulate hosts that may support the maintenance and dissemination of CFT, is impacting the ability of state and federal agencies to keep the national herd free of CFT and consequently bovine babesiosis.
The number of CFT outbreaks within and outside the permanent quarantine zone fluctuates with time (Fig. (Fig.1).1). A significant incursion of CFT took place in the 1970s. From a total of 170 outbreaks recorded in 1973, 112 occurred outside of the permanent quarantine zone. It took six years to re-eradicate the ticks at a significant cost to producers and agencies with mandated control responsibilities. During the last five years, the level of CFT activity in the U.S. has once again increased substantially. The largest number of infested premises in the permanent quarantine zone was initially recorded in 2005, but that record was broken again in 2008 when CFT were detected in 85 premises. A sustained spillover of CFT into the free zone also has been noted since 2004. There appears to be a spike in the number of outbreaks in the permanent quarantine zone prior to the explosion of outbreaks in the free zone that was recorded in 1973 (Fig. (Fig.1).1). Not only do we see a similar pattern now, but also the development of outbreaks in the permanent quarantine zone suggests that the number and extent of outbreaks in the free zone may continue to increase (Fig. (Fig.1).1). This situation is indeed an emergency that requires both immediate and long-term interventions.
Surveillance is critical to determine if changes in environmental factors are affecting tick populations and/or pathogen transmission dynamics . Regulations for CFT surveillance are established and applied to domestic cattle populations. Current surveillance for CFT is designed for detection of infestations on cattle moved into the U.S. But, the landscape in South Texas has changed considerably in the recent past. For example, the number of non-traditional farms and properties maintained exclusively for hunting has increased substantially. These factors, combined with the increased densities of native (i.e. white-tailed deer), and non-native (exotic) ungulate species, have complicated surveillance. White-tailed deer and exotic ungulate species may support CFT populations in the absence of cattle, and this may add a new dimension to tick population dynamics in this region. However, adequate surveillance tools and methodologies have not been developed for native and exotic ungulate species. The lack of sufficient surveillance tools for detection of CFT on alternative hosts in the absence of cattle is urgently needed to maintain a successful eradication program.
Native and non-native species of wild ungulates, particularly white-tailed deer, are a major complicating factor in CFT eradication efforts. CFT eradication in pastures vacated of cattle was considered impossible as long as white-tailed deer remained within an area . Approximately 20,000 white-tailed deer had to be culled (Hourrigan, unpublished data) before CFT eradication in Florida was officially completed in 1961 . The suitability of cervid and non-domestic bovid species as hosts for CFT is well documented [12-15]. In South Texas, complexities of the expanding infestations are compounded by agricultural practices, as well as recreational, environmental and ecological conditions promoting an abundance of white-tailed deer and non-native wild ungulates. Hunter-killed wildlife surveillance in Zapata and Starr Counties revealed that during fiscal year 2009 at least 30% of all the CFT infestations in the permanent quarantine zone occurred in white-tailed deer. Additionally, Cantu et al. [16,17] documented the exposure of white-tailed deer to B.bovis and B.bigemina. These findings highlight the need to understand risks to cattle populations from CFT infestations and Babesia infection in native and non-native ungulate populations.
To date, only one non-native ungulate species, the nilgai antelope (Boselaphus tragocamelus), has been evaluated for host suitability . Non-native ungulate populations have expanded considerably in Texas and other states over the last 30 years. Texas is estimated to have more than 70 species of non-native ungulates, numbering over 200,000 animals . Incomplete fencing and poor maintenance of high fences has allowed many animals to escape, and at least five species of exotic ungulates exist as free ranging populations in Texas and other regions of the U.S. where they are commonly farmed or have been intentionally released [18-26]. These animals pose a continued risk for maintaining and disseminating CFT populations.
Some species of non-native wild ungulates may also contribute to the re-establishment of CFT infestations and Texas cattle fever. Two separate efforts conducted in 2009 confirmed that a herd of nilgai antelope in Cameron County, Texas was infested with CFT. Additionally, nilgai were reported to be susceptible to infection with Babesia spp. in India .
The roles that white-tailed deer and non-native ungulate species play in the dissemination of CFT across the landscape are poorly understood. In addition, it is unclear how this potential dissemination of CFT may be linked to current and past infestations of cattle.
A small number of studies have been published on cattle-CFT interactions during the blood-feeding process [28,29]. Results from these studies will advance our understanding of the immunological basis for innate and acquired resistance to CFT in cattle. However, the molecular basis and effects on host defense mechanisms of bioactive factors in the saliva of CFT remains largely unexplored. Much work needs to be done to provide the foundation for development of novel control strategies for disease prevention.
Various assays have been developed and used for diagnostic purposes in research on Texas cattle fever [30,31]. Complement fixation, indirect fluorescent antibody and polymerase chain reaction tests are adequate for early detection and can be used for long-term carriers. Competitive ELISA yields positive results, but this technological platform is not currently commercially available [30,31]. Cattle imported from Mexico are not tested for Babesia because the tick vector had been contained within the permanent quarantine zone and current CFT eradication measures appear to have prevented outbreaks of clinical Texas cattle fever. However, the emerging re-infestation by CFT increases the risk for the re-emergence of Texas cattle fever in the U.S. CFT eradication achieved since 1943 also obviated the need to use babesiacidal drugs in cattle. Thus, there is no drug registered in the U.S. to treat bovine babesiosis. The risk is amplified further by the suspected ability of wildlife to serve as competent reservoirs for B.bovis and B. bigemina [17,27].
Tick "scratching" is the method approved to detect and identify CFT infestations in cattle and deer. However, larvae infesting animals can readily escape human detection. Serologic tests and other sensing technologies should be explored for their utility to test cattle and wildlife for CFT infestation. For example, antibodies to unique salivary proteins in other tick vectors can be detected by ELISA . This technique may allow larval detection and an ELISA test would be amenable to standardization. However, tick "scratching" yields immediate results on site, while an ELISA would require dedicated equipment and results take longer to develop. In addition, serologic assays might not be able to distinguish between current and previous infestations. Increased efficiency for CFT detection may be achieved through the combination of different methods. "Scratching" of live white-tailed and other wildlife is more problematic. This is especially challenging in areas devoid of cattle that are adjacent to quarantined premises. The challenge is complicated further by the lack of a sentinel system for the presence of CFT in the landscape when the option to vacate cattle from premises is exercised by the landowner.
Babesia vaccines against B. bovis and B. bigemina consisting of living attenuated parasites are in use in endemic areas worldwide. However, live Babesia vaccines have a number of limitations, including short shelf life, possibility of reversion to virulence, the need of a cold chain, and the establishment of persisting Babesia infections in the vaccinated areas. Additionally, vaccination with live vaccines causes the animals to become seropositive against Babesia thus making difficult to distinguish vaccinated from infected animals upon serological screening, confounding diagnostic efforts. Ideally vaccines should overcome these limitations, and preferably be based on strains that are not transmissible by ticks. In the context of the current increased risk of a Babesia outbreak that might cause substantial economic damage, it would be practical to have both B. bovis and B. bigemina live vaccines, or at least vaccine-ready attenuated strains, available in case urgent preventive measures are required. However, such vaccines are not licensed for use in the U.S. currently. Research efforts are currently being directed towards the use of a novel transfection system to aid in the development of better defined non tick-transmissible vaccine strains that may overcome some of the limitations of current vaccines . Together with the availability of the B. bovis genome , Babesia transfection techniques can be helpful for: (i) helping to define virulence factors by gene knock-out techniques; (ii) the production of viable and attenuated Babesia strains that are deficient in known virulence factors; (iii) introducing antigenic molecular markers that may help to discriminate vaccinated from naturally infected animals; (iv) producing Babesia strains that express protective tick antigens, such as Bm86, that may elicit dual protection, against Babesia disease and tick infestation. Effective subunit vaccines would be ideal for prevention of bovine babesiosis but no one is yet available . Developing subunit vaccines will likely require better characterization of protective immune responses, the host-parasite relationship, further identification of vaccine candidate antigens, and effective methods of vaccine delivery .
Cattle drives in the nineteenth century facilitated the expansion of CFT populations throughout the U.S . The former geographic range of CFT in the U.S. covered 14 southern states including Missouri, Kentucky and southern California. In 1868, a major outbreak of cattle tick fever killed 15,000 cattle in Illinois and Indiana following the importation of apparently healthy cattle from Texas . Following definitive studies done in collaboration with Frederick L. Kilborne which lead to our understanding of how the disease was transmitted to cattle by CFT, Theobald Smith stated, "Eliminate the ticks on cattle and you eradicate the ticks because they cannot live elsewhere" . That concept is untenable today despite heroic efforts by Cattle Fever Tick Eradication Program personnel operating with limited resources and is inadequate to sustain CFT eradication in the U.S.
Bovine babesiosis and CFT are endemic in Mexico. Almost a million cattle are imported annually into the U.S. from Mexico through Texas. Stray animals, smuggling of livestock, free crossing of wildlife across the U.S. - Mexico border, and pervasive acaricide resistance in Mexico are major risk factors for re-emergence of CFT and bovine babesiosis in the U.S. The organophosphate compound Coumaphos is the only acaricide approved for official use by the Cattle Fever Tick Eradication Program in dipping vats since 1970. Another challenge for total eradication is that CFT have no natural enemies in the U.S. since they are an invasive species that was brought into the country with livestock by European settlers.
Despite recent technological advancements that fueled the development and commercialization of vaccines based on the tick antigen Bm86 in Australia and certain Latin American countries , acaricides remain the principal means commercially accessible for tick eradication. However, development and commercialization of novel acaricides is challenging and costly . This situation reinforces the need for alternative approaches to control tick infestations [41,42].
Tick vaccines have been developed that induce immunological protection of vertebrate hosts against tick infestations. The feasibility of controlling tick infestations through immunization of hosts with selected tick antigens was demonstrated with the development of vaccines based on recombinant Bm86 protein derived from the gut of Rhipicephalus (Boophilus) spp. and used to induce a protective immune response that reduced infestations on cattle [39,41,42]. These products represent the first generation of tick vaccines to be commercialized. Control of ticks by vaccination has the advantages of being cost-effective, reducing environmental contamination and prevention of the selection of drug resistant ticks that result from repeated acaricide application. Development of vaccines against ticks would also allow for inclusion of multiple antigens that could target a broad range of tick species and may also prevent pathogen transmission. Vaccines that target tick saliva molecules essential for successful blood feeding and pathogen transmission are an active area of research.
The utility of tick vaccines based on Bm86, used alone or in combination with acaricides, for eradication purposes needs to be explored. Gavac® is one of the Bm86-based tick vaccines, which is registered and commercially available in Mexico, but not in the U.S. Tick vaccines have to be registered in the U.S. before business concerns can sell them to producers for use in cattle. The development of a critical path for registration and the need for production domestically would need to be considered if Bm86-based tick vaccines show potential as a tool for CFT eradication. Assessing this potential requires the conduct of trials in the U.S. before those anti-tick vaccines are licensed for use in South Texas.
See Table Table11 for list of research needs in bovine babesiosis.
Human babesiosis was first reported in 1957, more than a half century after the problem of cattle babesiosis was recognized. Since that time, the epidemiology of human babesiosis has changed from a few isolated cases in coastal New England to the recognition of expanding endemic areas in the northeastern and mid-western United States and episodic cases reported in Europe, Asia, Africa and South America . Babesia microti, the most common Babesia species that causes human babesiosis, is endemic in much of the Northeast and northern Midwest and is also the most frequent transfusion transmitted microbial agent in the United States . Babesiosis is most often a mild to moderate illness that lasts for about a week. It also may have significant associated morbidity and a mortality rate that ranges from 3-5% in previously health people to greater than 20% in immunocompromised hosts [43,45].
Babesiosis is an emerging infection among humans. There has been a progressive increase in reported cases each year over the past 25 years in northeastern and northern mid-western states, including recently described cattle-associated Babesia divergens and Babesia divergens-like cases . No national reporting requirement currently exists and the number of actual cases is thought to be greatly underestimated. Babesia infection has also been increasingly identified as a cause of disease in people throughout the world. Severity of infection ranges from asymptomatic to fulminant disease resulting in death [43,45]. The majority of healthy adults experience a mild to moderate illness. Immunocompromised individuals are at the highest risk of severe disease, including those with malignancy, HIV infection, absence of a spleen, use of immune-suppressive drug therapy, and people over the age of 50 years. Asymptomatic carriers present a considerable safety risk to the blood supply and babesiosis is the most commonly reported infectious agent transmitted by blood transfusion in the U.S .
As with CTF in Texas, the risk of human babesiosis in the northern US in influenced by the distribution and abundance of wildlife species. Rodent reservoirs of B. mictori are ubiquitous, but enzootic transmission is only known to occur in the presence of I. scapularis .
The primary cause for the emergence of human babesiosis is due to an increase in white-tailed deer populations in the Northeast and upper Midwest which host the adult stage of I. scapularis. Controlling tick infestations in white-tailed deer or elimination of the deer population may sharply reduce the risk of babesiosis and other I. scapularis-borne infections such as Lyme disease and human anaplasmosis. Like other tick-borne disease systems where white-tailed deer are a keystone host, deer-targeted tick control in the Northeast resulted in an overall decrease in the human risk for exposure to Borrelia burgdorferi and Anaplasma phagocytophilum . Additionally, a population of I. scapularis ticks was eliminated after deer were removed from Monhegan Island, Maine . The local elimination of white-tailed deer or methods for preventing I. scapularis from feeding upon deer, such as acaricides or anti-tick vaccines, seems to provide the most promising option for preventing human babesiosis as well as other I. scapularis-borne pathogens .
Diagnosis of human babesiosis depends on laboratory testing techniques because symptoms are relatively non-specific. Definitive diagnosis of Babesia infection is generally made by microscopic identification of the organism on thin blood smear, amplification of Babesia DNA by PCR and detection of Babesia antibody by ELISA . Antimicrobial therapy consists of atovaquone and azithromycin or clindamycin and quinine. Only two standard antimicrobial combinations currently exist. The combination of atovaquone and azithromycin is effective and well tolerated and is the most commonly used antibiotic treatment of human babesiosis . Rare clinical resistance in a few immunocompromised hosts has been described. The other combination of clyndamicin and quinine is especially useful in treatment of severe Babesia cases, but is often poorly tolerated. Some immunocompromised hosts do not clear infection for months or years despite multiple courses of antibiotics that can result in a mortality rate as high as 20% . Exchange transfusion may be life saving in severe cases. The use of multiple prevention strategies is recommended and consists of personal, residential and community approaches .
Babesiosis vaccines have not been developed for humans. Tick vaccines may help control of human babesiosis by reducing the risk of pathogen transmission from animals to humans after vaccination of animal reservoir species.
See Table Table11 for list of research needs in human babesiosis.
Keeping CFT eradicated from the U.S. is a current and critical agricultural biosecurity issue of national relevance. Human babesiosis is an emerging disease of public health concern in the U.S., especially for the immunocompromised and people receiving blood transfusions. The One Health approach to the discussion of current issues on emerging babesioses during the workshop helped identify commonalities in research and development initiatives that are critically important to mitigate their impact on human and animal health. We suggest that research be prioritized to these areas where considerable gaps in knowledge and technology were identified: 1) tick vector ecology studies addressing the epidemiology of human and animal babesioses; 2) the molecular basis of host-Babesia and host-tick interactions in humans, livestock and wildlife; 3) implications of the wildlife-livestock interface on the apparent resurgence of CFT outbreaks and the reservoir status of white-tailed deer and non-native wild ungulates for B. bovis and B. bigemina; 4) integrated approaches for sustainable CFT eradication to include research on safer acaricides with new modes of action and the development of more effective formulations using active ingredients already registered or approved with the regulatory agencies; 5) diagnostic and prophylactic interventions for control of human and animal babesioses; 6) assessing the utility of prophylactic intervention with Bm86-based vaccines, or through the use of other tick protective antigens, in CFT eradication efforts as well as tick-vaccines and delivery methods for white-tailed deer in human babesioisis prevention. Initiatives to pursue the research needs presented here require adequate funding, but the One Health concept offers the opportunity to focus interdisciplinary research efforts that maximize the use of limited resources through collaborations between investigators with expertise in the human and veterinary medical sciences.
The authors declare that they have no competing interests.
All coauthors in the paper contributed to drafting the manuscript.
We thank Angie Heimann, Beth Lemeilleur, Barbara Pagel, Barbara Eastwood, and Roger Sorenson for impeccable organizational support. Dr. Renato Andreotti made helpful comments on the draft report. Melinda May provided invaluable support to produce the graph. This paper is the results of a workshop convened by the United States Department of Agriculture - Agricultural Research Service and the Center for Ecoepidemiology, Yale University School of Medicine on 22nd and 23rd of April 2009 in McAllen, Texas. Other members of the Group for Emerging Babesioses and One Health Research and Development in the U.S. are: Dr. Sandra A. Allan, Mosquito and Fly Research Unit, Research Entomologist, 1600 - 1700 SW 23rd Drive, Gainesville, FL 32608, (352) 374-5940 vog.adsu.sra@nallA.ydnaS; Dr. José M. Ávila-Curiel, Ph.D., Researcher in Grazing Animal Nutrition, INIFAP - SAGARPA, Francisco Mendoza No. 212, Col. Azuncion Avalos, Cd. Madero, Tamaulipas, Mexico, CP 89416, (836) 276-0023/24; Cell: (833) 167-7158, email@example.comA; Dr. Richard Bishop, Senior Molecular Biologist, International Livestock Research Institute (ILRI), P.O. Box 30709, GPO 00100, Nairobi, Kenya, Tel: +254(0)20 4223000 (switchboard) 4223359 (office), firstname.lastname@example.org; Dr. Antonio Cantu, INIFAP - SAGARPA, Universidad Autónoma, Tuxtla Gutiérrez, Chiapas, Mexico, email@example.comC; Dr. James R. Coppedge, Associate Area Director, USDA-ARS-Southern Plains Area, 1001 Holleman Drive East, College Station, TX 77840-4147, (979) 260-9346, firstname.lastname@example.org; Mr. Lavoyger Durham, South Texans' Property Rights Association, P.O. Box 397, Falfurrias, Texas 78355, (361) 522-5194; Mrs. Susan Durham, South Texans' Property Rights Association, P.O. Box 397, Falfurrias, Texas 78355, (361) 522-5194, gro.arpts@nasus; Dr. Jim Gallagher, Assistant Professor and Extension Wildlife Specialist, Wildlife and Fisheries Science Dept., Texas AgriLife Extension Service, PO Box 1849, 1619 Garner Field Road, Uvalde, TX 78802-1849 830-278-9151, ude.umat.ga@rehgallagfj; Dr. Patricia Holman, Research Assistant Professor, Department of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences Texas A&M University College Station, TX 77843-4467, (979) 845-4202, ude.umat.mvc@namlohp; Mr. Larry Jung, Assistant Director Field Operations, Cattle Fever Tick Eradication Program, P.O. Box 567, Del Rio, Texas 78841, Phone # 830-775-5452, vog.adsu@gnuJ.D.yrraL; Dr. James B. Lenarduzzi, Area 5 Director, Animal Health Commission, 3811 N. Saint Marys St, Beeville, Texas 78102-2128, (361) 358-3234, su.xt.etats.chat@lsemaj; Dr. Byron E. Rippke, Director, Policy, Evaluation & Licensing, USDA Center for Veterinary Biologics, 1920 Dayton Road, Ames, IA 50010, (515) 337-6101, vog.adsu.sihpa@ekppiR.E.noryB; Mr. Sam Rodriquez, R Y Livestock Sales, Rio Grande City, Texas, moc.loa@masnamelttac; Mr. Fausto Salinas Jr., F&M Farms & Cattle Company, moc.liamg@tsuafsanilaS; Dr. Greta Schuster, Texas A & M University, Associate Professor - Agronomist, Department of Agronomy & Resource Sciences, MSC 228 Kleberg AG Bldg. RM 116, Kingsville, Texas 78363-8202, (361) 593-4116, ude.kumat@2002sguk.